Literature DB >> 14675669

VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer.

Cheung Wong1, Theresa L Wellman, Karen M Lounsbury.   

Abstract

OBJECTIVE: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that is elevated in epithelial ovarian cancer. Hypoxia inducible factor-1alpha (HIF-1alpha) is a transcription factor that plays a regulatory role in the expression of VEGF. Currently, there is limited information regarding VEGF and HIF-1alpha expression in epithelial ovarian cancer specimens. The objective of this study was to measure VEGF and HIF-1alpha expression in epithelial ovarian cancer samples and to compare VEGF and HIF-1alpha expression between ovarian cancer and normal ovarian tissue
METHODS: . Serial sections of paraffin-embedded ovarian tissues from a study group of 16 control patients and 37 patients diagnosed with epithelial ovarian cancer were analyzed for expression of VEGF and HIF-1alpha using immunohistochemistry.
RESULTS: There was a strong correlation between the average expression scores of VEGF and HIF-1alpha expression (r(2) = 0.991). There was a significant increase in expression of VEGF in stage III and IV tumors over that in controls (P < 0.005). There was also a significant increase in HIF-1alpha expression in stage III and IV tumors over that in controls (P < 0.005 and P < 0.05, respectively).
CONCLUSION: VEGF and HIF-1alpha are both expressed in epithelial ovarian cancer. VEGF expression correlated with HIF-1alpha expression, suggesting that HIF-1alpha may contribute to the overexpression of VEGF observed in epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675669     DOI: 10.1016/j.ygyno.2003.08.022

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  29 in total

1.  Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia.

Authors:  Jessica M Cassavaugh; Sarah A Hale; Theresa L Wellman; Alan K Howe; Cheung Wong; Karen M Lounsbury
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

2.  Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J Klein-Szanto; Robert A Burger; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

3.  Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction.

Authors:  Sylvie Lorenzen; Ben Panzram; Gisela Keller; Florian Lordick; Ken Herrmann; Karin Becker; Ruppert Langer; Markus Schwaiger; Jorg Rudiger Siewert; Katja Ott
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

4.  Pathological and prognostic significance of hypoxia-inducible factor 1α expression in epithelial ovarian cancer: a meta-analysis.

Authors:  Yue Jin; Haolu Wang; Xiaowen Liang; Jun Ma; Yu Wang
Journal:  Tumour Biol       Date:  2014-05-21

5.  Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.

Authors:  Monica Binaschi; Cecilia Simonelli; Cristina Goso; Mario Bigioni; Carlo Alberto Maggi
Journal:  Exp Ther Med       Date:  2011-01-14       Impact factor: 2.447

Review 6.  Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

7.  Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.

Authors:  Anne M Schultheis; Georg Lurje; Katrin E Rhodes; Wu Zhang; Dongyun Yang; Agustin A Garcia; Robert Morgan; David Gandara; Sidney Scudder; Amit Oza; Hal Hirte; Gini Fleming; Lynda Roman; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

8.  SNAIL gene inhibited by hypoxia-inducible factor 1α (HIF-1α) in epithelial ovarian cancer.

Authors:  Pengnan Zhang; Yanmei Liu; Youji Feng; Shujun Gao
Journal:  Int J Immunopathol Pharmacol       Date:  2016-04-04       Impact factor: 3.219

9.  Evaluation of Hypoxia Inducible Factor-1α and Glucose Transporter-1 Expression in Non Melanoma Skin Cancer: An Immunohistochemical Study.

Authors:  Iman Seleit; Ola Ahmed Bakry; Dalia Rifaat Al-Sharaky; Rania Abdel Aziz Ragab; Shimaa Ahmed Al-Shiemy
Journal:  J Clin Diagn Res       Date:  2017-06-01

Review 10.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.